IP Library Granted Patent US 11,890,322
Granted Patent B2
US 11,890,322 · App. 17/373,877 · Granted Feb 6, 2024

Methods for promoting wound healing and hair growth comprising GDNF administration

Inventors: Robert E. Braun (Bar Harbor, ME); Manju Sharma (Bar Harbor, ME)
Assignee: The Jackson Laboratory
A61K38/185A61K8/64A61Q7/00C07K14/4756
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,890,322
App. No.
17/373,877
Granted
Feb 6, 2024
Kind
B2
Abstract

The present invention generally relates to uses of glial cell line-derived growth factor (GDNF) in cutaneous wound healing and hair growth. Methods of effecting hair growth and/or wound healing which feature administration of GDNF, or a biologically active fragment thereof, to subjects, e.g., human subject, are disclosed herein. The invention relates also to formulations and kits for achieving the indicated pharmaceutical advantages.

Claims (22)

1. A method for promoting hair growth comprising:

administering to skin comprising hair follicles of a subject in need thereof a therapeutically effective dose of a topical formulation comprising recombinant human glial cell-derived neurotrophic factor (GDNF),

wherein the therapeutically effective dose is 1-10 mg, 10-20 mg, 20-30 mg, or 30-40 mg, thereby promoting an increase in hair follicle number of the skin of the subject.

2. The method of claim 1 , wherein the subject has androgenetic alopecia.

3. The method of claim 2 , wherein the subject is a female.

4. The method of claim 1 , wherein the subject has acute or chronic telogen effluvium.

5. The method of claim 1 , wherein the topical formulation is administered to the scalp of the subject.

6. The method of claim 1 , wherein the topical formulation is an emulsion.

7. The method of claim 6 , wherein the emulsion is a continuous phase emulsion.

8. The method of claim 6 , wherein the emulsion is a disperse phase emulsion.

9. The method of claim 6 , wherein the emulsion is a cream, lotion, ointment, or gel.

10. The method of claim 6 , wherein the emulsion is an oil-in-water emulsion or a water-in-oil emulsion.

11. The method of claim 6 , wherein the emulsion is a microemulsion.

12. The method of claim 1 , wherein the therapeutically effective dose is administered daily for at least 3-5 days.

13. The method of claim 1 , wherein the recombinant human GDNF is obtained from plant cells.

14. The method of claim 1 , further comprising, prior to the administering:

obtaining the recombinant human GDNF from plant cells; and

formulating the topical formulation comprising the recombinant GDNF.

15. The method of claim 14 , wherein the topical formulation is administered to the scalp of the subject.

16. The method of claim 15 , wherein the therapeutically effective dose is administered daily for at least 3-5 days.

17. The method of claim 15 , wherein the subject is a female.

18. The method of claim 1 , wherein the therapeutically effective dose promotes a 25% increase in hair follicle number over a period of 3-4 months.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2022
From: BRAUN, ROBERT E.; SHARMA, MANJU
To: THE JACKSON LABORATORY
Reel/Frame 061853/0678 →
Continuity (4)
Continuation 16452459 · Jun 25, 2019
Division 14775386
Provisional Application 61787870 · Mar 15, 2013
Related Publication 20220062381A1 · Mar 3, 2022
Cited By (1)
US 12,357,674